HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Pipeline

AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib, last Monday, Revolution Medicines is not resting on its laurels. The Bay Area biotech spent several recent days in San Diego highlighting earlier data for its lead candidate and the rest of its pipeline.

By FierceBiotech · Apr 22, 2026 · via FierceBiotech
AACR: Revolution sees pancreatic cancer win as 'tip of the iceberg' as RAS wave rises

Image: FierceBiotech

Tags
pipelineformat:headlineheadlineFierceBiotech
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Pipeline
All Pipeline →
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
PipelineFiercePharma ↗
In a Merck Litespark shocker, Welireg triplet misses the mark in first-line kidney cancer
After prevailing in two kidney cancer trials in the refractory and early-stage settings, Merck & Co.’s blo…
Apr 22, 2026
FDA approves once-daily HIV pill from Merck
PipelineEndpoints News ↗
FDA approves once-daily HIV pill from Merck
A new HIV treatment will soon come to market, and it will spearhead Merck’s attempt to be one of the leading d…
Apr 21, 2026
STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem
PipelineSTAT News ↗
STAT+: At AACR, a provocative use of CAR-T, Merck’s new thing and cancer’s geography problem
At AACR, a bold use of CAR-T raises hopes and provocative questions about its use in smoldering multiple myelo…
Apr 20, 2026